Advancing Tuberculosis Vaccination: Immunological Insights and Emerging Strategies for Improved Protection.
- 1Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA.
- 2Department of Medical Education, Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA.
- 3Department of Medicine and Oncology, University of Texas Rio Grande Valley, Edinburg, TX 78541, USA.
Abstract
Tuberculosis (TB) remains one of the leading causes of infectious disease mortality worldwide despite widespread Bacille Calmette-Guérin (BCG) vaccination and decades of control efforts. The limited and variable efficacy of current vaccination strategies, particularly against adult pulmonary disease, highlights the need for a deeper understanding of the host immune mechanisms that determine protection against Mycobacterium tuberculosis. While traditional approaches to TB vaccine development have largely focused on pathogen-specific immunity and clinical efficacy, emerging evidence suggests that successful TB control may depend equally on the strategic modulation of host immune responses. This narrative review examines the immunological basis of TB vaccination, emphasizing how contemporary vaccine platforms reshape both innate and adaptive immunity. We discuss the roles of trained immunity, T-cell function, immune memory, and mucosal immune responses in mediating protection, as well as the mechanisms by which M. tuberculosis evades immune surveillance. The review further explores next-generation vaccine technologies, including protein-adjuvant, viral-vectored, live-attenuated, and mRNA-based vaccines, highlighting their distinct immunological targets. Particular attention is given to mucosal immunity, systems vaccinology, and the ongoing search for reliable correlates of protection, which collectively offer new opportunities to improve vaccine design and evaluation. Finally, we examine host-directed immunomodulatory approaches, immune-engineering strategies, and precision vaccinology as emerging paradigms for TB prevention. By reframing TB vaccines as instruments for immune reprogramming rather than solely pathogen-specific interventions, this review provides an integrated perspective on how advances in immunology may accelerate progress toward global TB control and the goals of the WHO End TB Strategy.
Related
- Editorial: Measuring vaccination perception, confidence, and uptake: advancing instrument development and validation
- Histomonas meleagridis infection and vaccination protection in chickens -- a metabolomics study
- Shared Clinical and Immunological Features of Post-Acute COVID-19 and Post-Acute COVID-19 Vaccination Syndromes
- Real-World Effectiveness of Maternal RSVpreF Vaccination and Durability of Infant Protection
- Immunological Challenges and Emerging Strategies in Dengue Virus Vaccine Development.
BibTeX
@article{zhang2026advancing,
title = {{Advancing Tuberculosis Vaccination: Immunological Insights and Emerging Strategies for Improved Protection.}},
author = {Zhicheng Zhang and Crystal Sanchez and Derek Baker and Jeries Bawardi and Victoria Renteria and Sheralyn Sanchez and Subramanian Dhandayuthapani and Jessica Chacon},
journal = {Vaccines},
year = {2026},
month = oct,
doi = {10.3390/vaccines14100896},
url = {https://europepmc.org/article/MED/42931425},
note = {CC BY},
}
RIS
TY - JOUR
TI - Advancing Tuberculosis Vaccination: Immunological Insights and Emerging Strategies for Improved Protection.
AU - Zhicheng Zhang
AU - Crystal Sanchez
AU - Derek Baker
AU - Jeries Bawardi
AU - Victoria Renteria
AU - Sheralyn Sanchez
AU - Subramanian Dhandayuthapani
AU - Jessica Chacon
PY - 2026
DA - 2026/10/13
JO - Vaccines
DO - 10.3390/vaccines14100896
UR - https://europepmc.org/article/MED/42931425
AB - Tuberculosis (TB) remains one of the leading causes of infectious disease mortality worldwide despite widespread Bacille Calmette-Guérin (BCG) vaccination and decades of control efforts. The limited and variable efficacy of current vaccination strategies, particularly against adult pulmonary disease, highlights the need for a deeper understanding of the host immune mechanisms that determine protection against Mycobacterium tuberculosis. While traditional approaches to TB vaccine development have largely focused on pathogen-specific immunity and clinical efficacy, emerging evidence suggests that successful TB control may depend equally on the strategic modulation of host immune responses. This narrative review examines the immunological basis of TB vaccination, emphasizing how contemporary vaccine platforms reshape both innate and adaptive immunity. We discuss the roles of trained immunity, T-cell function, immune memory, and mucosal immune responses in mediating protection, as well as the mechanisms by which M. tuberculosis evades immune surveillance. The review further explores next-generation vaccine technologies, including protein-adjuvant, viral-vectored, live-attenuated, and mRNA-based vaccines, highlighting their distinct immunological targets. Particular attention is given to mucosal immunity, systems vaccinology, and the ongoing search for reliable correlates of protection, which collectively offer new opportunities to improve vaccine design and evaluation. Finally, we examine host-directed immunomodulatory approaches, immune-engineering strategies, and precision vaccinology as emerging paradigms for TB prevention. By reframing TB vaccines as instruments for immune reprogramming rather than solely pathogen-specific interventions, this review provides an integrated perspective on how advances in immunology may accelerate progress toward global TB control and the goals of the WHO End TB Strategy.
SN - 2076-393X
ER -